PARP Inhibitor PJ34 Protects Mitochondria and Induces DNA-Damage Mediated Apoptosis in Combination With Cisplatin or Temozolomide in B16F10 Melanoma Cells
PARP-1 inhibition has recently been employed in both mono- and combination therapies in various malignancies including melanoma with both promising and contradicting results reported. Although deeper understanding of the underlying molecular mechanisms may help improving clinical modalities, the com...
Main Authors: | Anna Maria Cseh, Zsolt Fabian, Ruben Quintana-Cabrera, Aliz Szabo, Krisztian Eros, Maria Eugenia Soriano, Ferenc Gallyas, Luca Scorrano, Balazs Sumegi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-05-01
|
Series: | Frontiers in Physiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphys.2019.00538/full |
Similar Items
-
Role of Akt Activation in PARP Inhibitor Resistance in Cancer
by: Ferenc Gallyas Jr, et al.
Published: (2020-02-01) -
Mitochondrial Protection by PARP Inhibition
by: Ferenc Gallyas Jr, et al.
Published: (2020-04-01) -
PARP inhibition attenuates acute kidney allograft rejection by suppressing cell death pathways and activating PI-3K-Akt cascade.
by: Karoly Kalmar-Nagy, et al.
Published: (2013-01-01) -
BGP-15 Protects against Oxidative Stress- or Lipopolysaccharide-Induced Mitochondrial Destabilization and Reduces Mitochondrial Production of Reactive Oxygen Species.
by: Katalin Sumegi, et al.
Published: (2017-01-01) -
Chronic PARP-1 inhibition reduces carotid vessel remodeling and oxidative damage of the dorsal hippocampus in spontaneously hypertensive rats.
by: Krisztian Eros, et al.
Published: (2017-01-01)